Published: Tue, May 09, 2017
Business | By Max Garcia

Sangamo Therapeutics (SGMO) Receives Daily Media Impact Rating of


NC owned 0.11% of Sangamo Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 61.87% of the company's stock. Wells Fargo & Company MN increased its position in shares of Sangamo Therapeutics by 9.0% in the third quarter. Columbus Circle Investors now owns 516,497 shares of the biopharmaceutical company's stock worth $2,391,000 after buying an additional 223,014 shares in the last quarter. Wasatch Advisors Inc. increased its stake in Sangamo Therapeutics by 0.4% in the third quarter. Teachers Advisors LLC now owns 164,728 shares of the biopharmaceutical company's stock valued at $502,000 after buying an additional 7,693 shares during the last quarter. BlackRock Fund Advisors boosted its stake in shares of Spark Therapeutics by 17.8% in the third quarter. BlackRock Advisors LLC now owns 215,072 shares of the biopharmaceutical company's stock worth $996,000 after buying an additional 1,001 shares in the last quarter. Finally, Piermont Capital Management Inc. raised its stake in Sangamo Therapeutics by 9.4% in the third quarter.

(NASDAQ:SGMO) was down -2.17% during the last trading session, with a day high of 4.65.

Sangamo BioSciences, Inc. has a 50 day moving average of 4.45 and a 200 day moving average of 3.90. Sangamo BioSciences, Inc. has a 52-week low of 2.65 and a 52-week high of 7.60.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Tuesday, February 28th. Piermont Capital Management Inc. now owns 169,079 shares of the biopharmaceutical company's stock worth $783,000 after buying an additional 14,460 shares during the last quarter. The business earned $16.30 million during the quarter, compared to analyst estimates of $1.32 million. On average, equities analysts expect that Sangamo Therapeutics will post ($1.25) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: "Sangamo Therapeutics (SGMO) Receives Daily Media Impact Rating of -0.15" was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and worldwide trademark & copyright law. The original version of this piece can be accessed at https://transcriptdaily.com/2017/05/06/sangamo-therapeutics-inc-sgmo-receives-average-recommendation-of-hold-from-analysts-updated.html.

Several analysts recently commented on ONCE shares.

10/23/2015 - Sangamo BioSciences, Inc. had its "buy" rating reiterated by analysts at Jefferies. Analysts have placed a $6.67 price target on Sangamo Therapeutics, Inc., suggesting a 45% gain from recent close.

08/08/2016 - Sangamo BioSciences, Inc. had its "buy" rating reiterated by analysts at Cowen. Wedbush restated a "neutral" rating and set a $4.00 price target on shares of Sangamo Therapeutics in a report on Wednesday, February 8th. Finally, Piper Jaffray Companies reiterated a "neutral" rating and set a $5.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, February 28th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the previous year is $5.67. They now have a United States dollars 5 price target on the stock. The stock was sold at an average price of $52.73, for a total value of $263,650.00. (NASDAQ:DERM), its shares were trading at $32.22 a retreat of $-0.25, on the trading floor. Also, Director Anand Mehra sold 84,654 shares of the company's stock in a transaction dated Wednesday, March 1st.

The share price of Sangamo BioSciences, Inc. The disclosure for this sale can be found here. They now have a Dollars 16 price target on the stock.

Spark Therapeutics, Inc is a gene therapy company. The focus for its Company is the development of human therapeutics.

Like this: